(Q46504504)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15910557%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

title

Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15910557%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

0 references

Bruce H Wolffenbuttel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15910557%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

A A M Franken

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15910557%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

H H Vincent

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15910557%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Dutch Corall Study Group

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15910557%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

language of work or name

English

0 references

publication date

1 June 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15910557%20AND%20SRC:MED&resulttype=core&format=json

Journal of Internal Medicine

12 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15910557%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

257

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15910557%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15910557%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

531-539

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15910557%20AND%20SRC:MED&resulttype=core&format=json

The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Management of dyslipidemia in the high-risk patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Apolipoprotein concentrations during treatment and recurrent coronary artery disease events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Rosuvastatin--a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Postprandial reverse cholesterol transport in type 2 diabetic patients: effect of a lipid lowering treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X

21 January 2018

Safety of rosuvastatin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01499.X